Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.
PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.
PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.
Learn more about Who We Are.
PPMI’s principal investigator, Dr. Ken Marek, will present on the initial findings of PPMI at the 8th Annual Parkinson’s Disease Therapeutics Conference on October 29 in New York City.
The audio from the latest PPMI Participant Study Update Call has just been posted. On the call, the principal investigator of the PPMI Imaging Core, John Seibyl, MD of Molecular Neuroimaging, LLC, discusses the role of imaging in PPMI. Listen to this call and find an archive of the past calls here.
A new study using PPMI data was published in the journal Movement Disorders exploring the relationship between cognitive impairment and dopaminergic deficits in unmedicated Parkinson’s patients.
PPMI was designed to be adaptable to changing needs, targets, and opportunities in research. In reflection of this, PPMI recently updated its study protocol to include new and revised procedures and assessments. View a summary of the latest changes.
A recent publication in the journal Parkinsonism and Related Disorders used PPMI data to find that more severe daytime sleepiness and fatigue are associated with greater cognitive impairment. The study’s researchers used PPMI data as well as data from two other studies in order to examine this relationship across the different stages of Parkinson’s.